Ryan Sugarman
Overview
Explore the profile of Ryan Sugarman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
Sugarman R, Betts K, Nie X, Hartman J, Nguyen H
Clin Ther
. 2023 Sep;
45(11):1155-1158.
PMID: 37748935
Purpose: Nivolumab, a programmed cell death protein (PD)-1 inhibitor, was approved by the US Food and Drug Administration in 2021 advanced/metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, in...
3.
Cytryn S, Moy R, Cowzer D, Shah R, Chou J, Joshi S, et al.
Lancet Oncol
. 2023 Sep;
24(10):1073-1082.
PMID: 37666264
Background: The addition of nivolumab to chemotherapy improves survival in patients with advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) adenocarcinoma; however, outcomes remain poor. We assessed the safety and activity...
4.
Rojas L, Sethna Z, Soares K, Olcese C, Pang N, Patterson E, et al.
Nature
. 2023 May;
618(7963):144-150.
PMID: 37165196
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours mutation-derived T cell neoantigens that are suitable for vaccines . Here in a phase I trial of adjuvant...
5.
Lin D, Nguyen H, Shah R, Qiao Y, Hartman J, Sugarman R
Gastric Cancer
. 2023 Mar;
26(3):415-424.
PMID: 36943511
Background: The phase 3 CheckMate 649 established superior overall survival of nivolumab in combination with chemotherapy (NIVO + chemo) compared with chemotherapy (chemo) alone as a first-line treatment for patients...
6.
Cowzer D, Wu A, Sihag S, Walch H, Park B, Jones D, et al.
Ann Surg
. 2023 Feb;
278(3):e511-e518.
PMID: 36762546
Objective: To determine the safety and efficacy of adding the anti-PD-L1 antibody durvalumab to induction FOLFOX and preoperative chemotherapy in locally advanced esophageal adenocarcinoma. Background: Neoadjuvant induction FOLFOX followed by...
7.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al.
N Engl J Med
. 2022 Jun;
386(25):2363-2376.
PMID: 35660797
Background: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a...
8.
Rehman H, Hakim N, Sugarman R, Seetharamu N, Saif M
J Oncol Pharm Pract
. 2020 Feb;
26(6):1511-1515.
PMID: 32067560
Case Report: Imatinib mesylate is a well-known tyrosine kinase inhibitor used to treat chronic myeloid leukemia, gastrointestinal stromal tumor, as well as a variety of other malignancies. As use of...
9.
Sugarman R, Patel R, Sharma S, Plenker D, Tuveson D, Saif M
Expert Opin Drug Metab Toxicol
. 2019 Jun;
15(7):541-552.
PMID: 31241371
: Pancreatic cancer (PC) remains a disease with a dismal prognosis. Despite accounting for only 3% of cancer diagnosis, 7% of all cancer deaths in the United States are from...
10.
Sugarman R, Tufano A, Liu J
BMJ Case Rep
. 2018 Feb;
2018.
PMID: 29437728
A 67-year-old right-handed woman presented with dysarthria, left upper extremity weakness and right-sided neglect of 3 hours duration. Imaging of the brain revealed acute right middle cerebral artery stroke; however,...